DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

ULTRAGENYX PHARMAC (NASDAQ: RARE)

120.93 5.11 (4.41%)

Quote as of


company name or ticker

Recent Quotes

RARE $120.93 4.41%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $115.09
Previous Close $115.82
Daily Range $115.09 - $121.38
52-Week Range $38.01 - $137.05
Market Cap $4.3B
P/E Ratio -57.05
Dividend (Yield) $0.00 (0.0%)
Volume 709,171
Average Daily Volume 673,214
Current FY EPS -$2.52

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

News & Commentary

Why Ultragenyx Pharmaceutical Inc. Stock Slumped

Ultragenyx shares aren't looking so "ultra" today after the company announced its intention to sell shares of common stock. Find out what this means for investors.

Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

First Week of September 18th Options Trading For Ultragenyx Pharmaceutical (RARE)

Benzinga's Top #PreMarket Losers

Stocks Hitting 52-Week Highs

Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Stud

Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

First Week of RARE February 2016 Options Trading

Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog

Ultragenyx Reports Positive 16-Week Interim Data from Pediatric Phase 2 Study of KRN23: No Serious A

Ultragenyx Reports Positive 16-Week Interim Data from Pediatric Phase 2 Study of KRN23: No Serious Adverse Events Reported, Sees Potential Conditional Approval Pathway in Europe

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q1 2015 Results - Earnings Call Transcript

Can Catalyst Pharmaceutical Surprise this Earnings Season? - Analyst Blog

See More RARE News...